Pipeline

December 15, 2019
Company Drug/Device Medical Condition Status
Nouscom NOUS-209 cancer Phase 1 trial initiated in subjects with microsatellite instable high gastric, colorectal and gastro-esophageal junction cancers in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab at multiple centers in the U.S.
EicOsis LLC EC5026 pain management Phase 1a trial initiated enrolling healthy subjects
Oncternal Therapeutics TK216 Ewing Sarcoma Phase 1b expansion cohort initiated enrolling 18 subjects with relapsed or refractory Ewing Sarcoma at seven sites across the U.S.
Helix Biopharma L-DOS47 advanced pancreatic cancer Phase 1b/2 trial initiated in 20 subjects with advanced pancreatic cancer at the HonorHealth Scottsdale Osborn Medical Center in Scottsdale, Arizona
ProQR QR-1123 autosomal dominant retinitis pigmentosa Phase 1/2 trial initiated enrolling 35 subjects with autosomal dominant retinitis pigmentosa at sites in North America
Rocket Pharmaceuticals RP-L102 Fanconi Anemia Phase 2 trial initiated in 12 pediatric subjects with Fanconi Anemia at Lucile Packard Children’s Hospital Stanford and Hospital Infantil Universitario Niño Jesús
ImaginAb 89Zr-Df-IAB22M2C cancer and immune system imaging Phase 2 trial initiated enrolling subjects with advanced and metastatic cancer at Penn Medicine in Philadelphia, Pa.
Viela Bio VIB4920 Sjögren’s syndrome Phase 2b trial initiated enrolling subjects with Sjögren’s syndrome
Tonix Pharmaceuticals TNX-102 SL fibromyalgia Phase 3 trial initiated enrolling 470 subjects at 40 U.S. sites
Ocugen OCU300 ocular graft versus host disease Phase 3 trial initiated enrolling 60 subjects with ocular graft versus host disease
Eli Lilly LOXO-292 non-small cell lung cancer Phase 3 trial initiated enrolling 400 subjects
CStone Pharmaceuticals avapritinib advanced gastrointestinal stromal tumors Phase 3 trial initiated enrolling subjects with advanced gastrointestinal stromal tumors in China
Can-Fite Biopharma Piclidenoson moderate to severe plaque psoriasis Phase 3 trial initiated enrolling 407 subjects with moderate to severe plaque psoriasis in Europe, Israel and Canada
InMed Pharmaceuticals INM-755 epidermolysis bullosa Clinical Trial Authorization acceptance granted by the MHRA
CStone Pharmaceuticals CS3005 cancer Clinical Trial Authorization acceptance granted by the TGA
STAAR Surgical EVO/EVO+ VISIAN Toric Implantable Collamer Lens myopia with astigmatism IDE approval granted by the FDA
Abeona Therapeutics EB-101 recessive dystrophic epidermolysis bullosa IND approval granted by the FDA
CSL Behring Hizentra chronic inflammatory demyelinating polyneuropathy Orphan drug designation granted by FDA
VistaGen Therapeutics PH94B neuroactive nasal spray social anxiety disorder Fast Track Designation granted by the FDA
Dermira lebrikizumab moderate-to-severe atopic dermatitis Fast Track Designation granted by the FDA
Equillium itolizumab lupus nephritis Fast Track Designation granted by the FDA
Sarepta Therapeutics Vyondys 53 duchenne muscular dystrophy Accelerated approval granted by the FDA
OrthoGrid Systems PhantomMSK Trauma imaging for orthopedic surgery 510(k) Clearance granted by the FDA
TechMah Medical LimaCorporate Smart SPACE Shoulder 3D Planner & 3D Positioner 3D pre-operative planning and 3D positioners for intra-operative positioning 510(k) Clearance granted by the FDA
etectRx ID-Cap ingestible event marker Clearance granted by the FDA
AptarGroup Unidose Liquid System acute repetitive seizures Clearance granted by the FDA
Dyve Biosciences DYV-700 acute gout pain Approval granted by the FDA
Meitheal Pharmaceuticals Enoxaparin Sodium Injection, USP preventing blood clots Approval granted by the FDA
Amgen AVSOLA moderate-to-severe rheumatoid arthritis Approval granted by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here